RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

<<cor may have no choice but to offer low-impacts as a class, for any and all indications.>>

Even Cortex has never had to do that, and won't. I think you are right that they'd try to steer partners to CX1942, which has both IV and oral formulations, if I recall correctly, as backups for CX717, also with both. 1942 would be the chronic use option.

They will not give up BOTH 1739 and 1942, the question is whether someone might demand IV717 and CX1739, since the latter already has safety data. They can always throw in another preclinical stage low impact as another backup,Les Street has made a bunch of them.

NeuroInvestment